Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558231 | 0.83 | MEN1 (0.42) | ALDH1A1LMNANPC1RAB9AMEN1 | |
| SCHEMBL1824023 | 0.82 | PPID (0.45) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL558631 | 0.81 | ALDH1A1 (0.57) | ALDH1A1PKMLMNAEPHX2MEN1 | |
| SCHEMBL22778042 | 0.80 | PPARG (0.49) | ALDH1A1EPHX2PPARG | |
| SCHEMBL14391600 | 0.80 | MAPK1 (0.33) | ALDH1A1PKMLMNAHPGDEPHX2 | |
| SCHEMBL558676 | 0.77 | MEN1 (0.45) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL558635 | 0.76 | TSHR (0.57) | ALDH1A1LMNAHPGDSMN1; SMN2MEN1 | |
| SCHEMBL4093144 | 0.75 | ALDH1A1 (0.62) | ALDH1A1PKMLMNAHPGDSMN1; SMN2 | |
| SCHEMBL5793985 | 0.75 | ALDH1A1 (0.62) | ALDH1A1PKMLMNAHPGDSMN1; SMN2 | |
| SCHEMBL21634929 | 0.74 | CARM1 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315761-B1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LTD (GB) | 2018-07-11 | — | — | EP | disclosed |
| US-8461339-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| EP-2315761-A1 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010007374-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130394-A1 | PHARMACEUTICAL COMPOUNDS | NR2C2, NR3C2, NR0B2 | ALDH1A1 4706/4885PKM 2263/4885LMNA 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.